Acrivon Therapeutics Inc. (ACRV)
Acrivon Therapeutics Inc. (ACRV) Stock Price, Analysis & Data
| Bid | 1.14 |
| Market Cap | 73.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -77.27M |
| Beta | 1.86 |
| EPS (ttm) | -2 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.88 |
| P/B (ttm) | 0.70 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2025 |
| Ask | 2.06 |
| Volume | 148,752 |
| Avg. Volume (20D) | 406,490 |
| Open | 1.75 |
| Previous Close | 1.73 |
| Day's Range | 1.70 - 1.75 |
| 52-Week Range | 1.25 - 3.56 |
| Analyst | Strong Buy |
| Price Target | 10.5 (510.47%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACRV
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are ...
Financial Performance
In 2025, Acrivon Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -77.91M, a decrease of -3.29%.
Financial StatementsAnalyst Forecast
According to 6 analyst ratings, the average rating for ACRV stock is "Strong Buy". The 12-month stock price forecast is 10.5, which is upside of 510.47% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
